Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Stem Cells ; 25(2): 437-46, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17284651

ABSTRACT

As the number of human embryonic stem cell (hESC) lines increases, so does the need for systematic evaluation of each line's characteristics and potential. Comparisons between lines are complicated by variations in culture conditions, feeders, spontaneous differentiation, and the absence of standardized assays. These difficulties, combined with the inability of most labs to maintain more than a few lines simultaneously, compel the development of reference standards to which hESC lines can be compared. The use of a stable cell line as a reference standard offers many advantages. A line with a relatively unchanging hESC-like gene and protein expression pattern could be a positive control for developing assays. It can be used as a reference for genomics or proteomics studies, especially for normalizing results obtained in separate laboratories. Such a cell line should be widely available without intellectual property restraints, easily cultured without feeders, and resistant to spontaneous changes in phenotype. We propose that the embryonal carcinoma (EC) line 2102Ep meets these requirements. We compared the protein, gene, and microRNA expression of this cell line with those of hESC lines and alternative reference lines such as the EC line NTERA-2 and the karyotypically abnormal hESC line BG01V. The overall expression profiles of all these lines were similar, with exceptions reflecting the germ cell origins of EC. On the basis of global gene and microRNA expression, 2102Ep is somewhat less similar to hESC than the alternatives; however, 2102Ep expresses more hESC-associated microRNAs than NTERA-2 does, and fewer markers of differentiated fates.


Subject(s)
Carcinoma, Embryonal/pathology , Embryonic Stem Cells/cytology , Animals , Biomarkers/metabolism , Carcinoma, Embryonal/genetics , Carcinoma, Embryonal/metabolism , Embryonic Stem Cells/metabolism , Flow Cytometry , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Humans , Immunophenotyping , Mice , MicroRNAs/genetics , MicroRNAs/metabolism , Oligonucleotide Array Sequence Analysis , Reference Standards , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, Cultured
2.
Nat Biotechnol ; 24(3): 351-7, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16501577

ABSTRACT

The application of human embryonic stem (hES) cells in regenerative medicine will require rigorous quality control measures to ensure the safety of hES cell-derived grafts. During propagation in vitro, hES cells can acquire cytogenetic abnormalities as well as submicroscopic genetic lesions, such as small amplifications or deletions. Many of the genetic abnormalities that arise in hES cell cultures are also implicated in human cancer development. The causes of genetic instability of hES cells in culture are poorly understood, and commonly used cytogenetic methods for detection of abnormal cells are capable only of low-throughput analysis on small numbers of cells. The identification of biomarkers of genetic instability in hES cells would greatly facilitate the development of culture methods that preserve genomic integrity. Here we show that CD30, a member of the tumor necrosis factor receptor superfamily, is expressed on transformed but not normal hES cells, and that CD30 expression protects hES cells against apoptosis.


Subject(s)
Carcinoma, Embryonal/metabolism , Carcinoma, Embryonal/pathology , Ki-1 Antigen/metabolism , Pluripotent Stem Cells/cytology , Pluripotent Stem Cells/metabolism , Biomarkers/analysis , Cell Culture Techniques , Cell Differentiation , Cell Line, Transformed , Cell Survival , Cell Transformation, Neoplastic , Cells, Cultured , Humans , Immunohistochemistry , Karyotyping
SELECTION OF CITATIONS
SEARCH DETAIL
...